Sangamo Therapeutics (SGMO) Registration Filing summary

Company overview and business model

• Focuses on genomic medicine, developing zinc finger (ZF) epigenetic regulators and engineered AAV capsids for neurological diseases.

• Pursues preclinical programs in epigenetic regulation therapies and neurotropic AAV capsids for CNS delivery.

• Develops integrases for targeted gene integration without genome cutting or reliance on native DNA repair.

Financial performance and metrics

• As of September 30, 2024, net tangible book value was $39.1 million, or $0.19 per share.

• After the offering, as adjusted net tangible book value would be $227.1 million, or $0.81 per share, assuming full sale at $2.70 per share.

• Company has a history of significant operating losses and anticipates continued losses; may never achieve profitability.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including R&D, administrative activities, and capital expenditures.

• Management has broad discretion over use of funds; proceeds may be invested in short-term, investment-grade securities pending use.